Calcium antagonists and renal disease

Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor.

The Journal of pharmacology and experimental therapeutics·1992

Nonadrenergic and noncholinergic arterial dilatation and venoconstriction are mediated by calcitonin gene-related peptide1 and neurokinin-1 receptors, respectively, in the mesenteric vasculature of the rat after perivascular nerve stimulation.

The Journal of pharmacology and experimental therapeutics·1992

Neuropeptide Y potentiates selectively the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus. I. Involvement of an atypical neuropeptide Y receptor.

The Journal of pharmacology and experimental therapeutics·1992

Neuropeptide Y inhibits alpha-MSH release from rat hypothalamic slices through a pertussis toxin-sensitive G protein.

Brain research·1992

Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy.

Kidney international·1992

Immunohistochemical distribution and biological activity of pituitary adenylate cyclase-activating polypeptide (PACAP) in the central nervous system of the frog Rana ridibunda.

The Journal of comparative neurology·1992

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Kidney international·2026

Asymptomatic serologic reactivation in patients with lupus nephritis in clinical remission: to treat or not to treat?

Kidney international·2026

What does it mean to win? Interpreting hierarchical kidney outcomes in hypertension trials.

Kidney international·2026

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection.

Kidney international·2026

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Open forum infectious diseases·2026

Long-Term Outcomes of Living-Related Kidney Donors Over 26 Years: A Study of 154 Cases From the Ibn Sina University Hospital Center in Rabat, Morocco.

Cureus·2026

The Role of Downstream Kynurenine Pathway Metabolites in the Modulation of Cardiovascular Disease Development in Chronic Kidney Disease.

International journal of tryptophan research : IJTR·2026

Association between Chinese herbal medicine and the composite outcome of repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a prospective cohort study.

Journal of geriatric cardiology : JGC·2026

Health economic evaluation of left atrial appendage closure in patients with atrial fibrillation and at high risk for stroke and bleeding: a study protocol.

Frontiers in health services·2026

Hypertension and Postoperative Outcomes: A Retrospective Cohort Study.

Anesthesiology research and practice·2026

Related Experiment Videos

Calcium antagonists and renal disease

Related Concept Videos

Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor.

Nonadrenergic and noncholinergic arterial dilatation and venoconstriction are mediated by calcitonin gene-related peptide1 and neurokinin-1 receptors, respectively, in the mesenteric vasculature of the rat after perivascular nerve stimulation.

Neuropeptide Y potentiates selectively the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus. I. Involvement of an atypical neuropeptide Y receptor.

Neuropeptide Y inhibits alpha-MSH release from rat hypothalamic slices through a pertussis toxin-sensitive G protein.

Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy.

Immunohistochemical distribution and biological activity of pituitary adenylate cyclase-activating polypeptide (PACAP) in the central nervous system of the frog Rana ridibunda.

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Asymptomatic serologic reactivation in patients with lupus nephritis in clinical remission: to treat or not to treat?

What does it mean to win? Interpreting hierarchical kidney outcomes in hypertension trials.

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection.

Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.

Long-Term Outcomes of Living-Related Kidney Donors Over 26 Years: A Study of 154 Cases From the Ibn Sina University Hospital Center in Rabat, Morocco.

The Role of Downstream Kynurenine Pathway Metabolites in the Modulation of Cardiovascular Disease Development in Chronic Kidney Disease.

Association between Chinese herbal medicine and the composite outcome of repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a prospective cohort study.

Health economic evaluation of left atrial appendage closure in patients with atrial fibrillation and at high risk for stroke and bleeding: a study protocol.

Hypertension and Postoperative Outcomes: A Retrospective Cohort Study.

Related Experiment Videos

Calcium antagonists and renal disease

Related Concept Videos

Related Articles